Ascendis Pharma A/S $ASND Stock Holdings Trimmed by Tema Etfs LLC

Key Points

• Tema Etfs LLC reduced its stake in Ascendis Pharma A/S by 67.9%, bringing its holdings to 6,106 shares worth $952,000.
• Several institutional investors, including HighTower Advisors LLC, significantly increased their positions in Ascendis Pharma, highlighting interest from the investment community.
• Ascendis Pharma A/S reported better-than-expected earnings, with an earnings per share of ($0.93) against a consensus estimate of ($1.42), and achieved $216.28 million in revenue for the quarter.

Tema Etfs LLC lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 67.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,106 shares of the biotechnology company's stock after selling 12,934 shares during the quarter. Tema Etfs LLC's holdings in Ascendis Pharma A/S were worth $952,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its stake in Ascendis Pharma A/S by 2.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company's stock valued at $1,337,000 after purchasing an additional 195 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ascendis Pharma A/S during the 4th quarter valued at approximately $28,000. Brooklyn Investment Group grew its stake in Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 273 shares in the last quarter. GF Fund Management CO. LTD. grew its position in shares of Ascendis Pharma A/S by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,544 shares of the biotechnology company's stock worth $241,000 after acquiring an additional 278 shares in the last quarter. Finally, Mariner LLC grew its position in shares of Ascendis Pharma A/S by 31.0% in the 4th quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock worth $297,000 after acquiring an additional 511 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND traded up $0.37 during mid-day trading on Monday, hitting $194.27. The company had a trading volume of 357,323 shares, compared to its average volume of 548,125. The stock has a market cap of $11.89 billion, a price-to-earnings ratio of -37.65 and a beta of 0.39. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $199.99. The firm's 50 day simple moving average is $180.19 and its two-hundred day simple moving average is $166.35.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. Equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on ASND shares. Cantor Fitzgerald lifted their target price on Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Cowen reiterated a "buy" rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Wells Fargo & Company reiterated an "overweight" rating and issued a $295.00 target price (up previously from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. UBS Group reiterated a "buy" rating and issued a $307.00 target price (up previously from $306.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Finally, Bank of America lifted their target price on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. Fifteen equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Buy" and a consensus price target of $243.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.